Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Naveed Aslam

Medical Oncology Troy, MI Medical Doctor

NPI 1235146002 CMS profile 192594

1380 Coolidge Hwy, Ste 200, Troy, MI 48084

Open in the dashboard

General payments

$28,601

583 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,764 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Naveed Aslam of Troy, MI is reported in the CMS Open Payments database as having received $28,601 across 583 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $22,764 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $531 6
2024 General $5,305 104
2023 General $2,696 114
2022 General $15,395 126
2021 General $1,409 77
2020 General $1,216 65
2019 General $2,049 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naveed Aslam
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Naveed Aslam were reported at $531. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Naveed Aslam Medical Oncology median Middle half National median
2019 $2,049 $968 $140–$6,658 $163
2020 $1,216 $747 $102–$5,891 $114
2021 $1,409 $430 $50–$4,098 $132
2022 $15,395 $812 $127–$4,907 $149
2023 $2,696 $957 $144–$5,248 $160
2024 $5,305 $1,042 $149–$5,650 $164
2025 $531 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $13,242 32 payments
  2. Genzyme Corporation $2,803 24 payments
  3. Novartis Pharmaceuticals Corporation $2,452 55 payments
  4. AstraZeneca Pharmaceuticals LP $1,138 48 payments
  5. Genentech USA, Inc. $814 33 payments
  6. Amgen Inc. $589 30 payments
  7. Lilly USA, LLC $481 22 payments
  8. Celgene Corporation $428 21 payments
  9. Janssen Biotech, Inc. $385 16 payments
  10. Astellas Pharma US Inc $384 13 payments
  11. Other $5,884 289 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,730 4 payments
  2. Food and Beverage $11,636 539 payments
  3. Travel and Lodging $2,747 7 payments
  4. Long term medical supply or device loan $1,795 18 payments
  5. Education $563 14 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $130 1 payment
Products named General payments · program years 2019–2025
  1. ENHERTU $13,138 27 payments
  2. KISQALI $1,869 35 payments
  3. LYNPARZA $397 11 payments
  4. Lenvima $343 18 payments
  5. CALQUENCE $308 16 payments
  6. KEYTRUDA $296 18 payments
  7. VERZENIO $293 17 payments
  8. TECENTRIQ $257 10 payments
  9. VENCLEXTA $257 12 payments
  10. Desara $254 1 payment
  11. Other $10,481 527 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,060

Median for Hematology-Oncology: 604

Drug cost

$977,117

Median for Hematology-Oncology: $1,306,514

Branded share of claims

23.4%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jakafi Ruxolitinib Phosphate Brand 25 $422,027
Tagrisso Osimertinib Mesylate Brand 11 $191,771
Revlimid Lenalidomide Brand 12 $139,178
Braftovi Encorafenib Brand 12 $120,548
Eliquis Apixaban Brand 36 $38,219
Xarelto Rivaroxaban Brand 37 $35,414
Exemestane Generic 26 $8,967
Anastrozole Generic 228 $8,460
Letrozole Generic 62 $1,876
Duloxetine Hcl Generic 81 $1,761

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$410,288

Of which drugs: $329,921

Medicare patients

243

Average age 75

Services billed

40,997

200 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 52%
Arthritis 43%
Osteoporosis 40%
Diabetes 30%
Ischemic heart disease 29%
Chronic kidney disease 25%
Depression 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 64 6,540 $131,867
Injection, zoledronic acid, 1 mg J3489 Office 14 101 $518
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 20 107 $90
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 19 184 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 64 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $806
$806 — —
ENJAYMO
  • GENZYME CORPORATION $194
$194 — —
RYBREVANT
  • Janssen Biotech, Inc. $139
$139 — —
VENCLEXTA
  • Genentech USA, Inc. $93
  • AbbVie, Inc. $21
$114 — —
ENHERTU
  • Daiichi Sankyo Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 64 with Patron

Records

583 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record